PE20080376A1 - Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina - Google Patents
Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridinaInfo
- Publication number
- PE20080376A1 PE20080376A1 PE2007000840A PE2007000840A PE20080376A1 PE 20080376 A1 PE20080376 A1 PE 20080376A1 PE 2007000840 A PE2007000840 A PE 2007000840A PE 2007000840 A PE2007000840 A PE 2007000840A PE 20080376 A1 PE20080376 A1 PE 20080376A1
- Authority
- PE
- Peru
- Prior art keywords
- fluorophenylpyridine
- sodium
- thrombin receptor
- receptor antagonist
- immediate release
- Prior art date
Links
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000007916 tablet composition Substances 0.000 title 1
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 235000019698 starch Nutrition 0.000 abstract 2
- 239000008107 starch Substances 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 102000003790 Thrombin receptors Human genes 0.000 abstract 1
- 108090000166 Thrombin receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 235000015424 sodium Nutrition 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81782106P | 2006-06-30 | 2006-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080376A1 true PE20080376A1 (es) | 2008-06-13 |
Family
ID=38895141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000840A PE20080376A1 (es) | 2006-06-30 | 2007-07-02 | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20080031943A1 (https=) |
| EP (2) | EP2491922B1 (https=) |
| JP (2) | JP5116764B2 (https=) |
| KR (1) | KR20090023670A (https=) |
| CN (2) | CN104922054A (https=) |
| AR (1) | AR061790A1 (https=) |
| AU (1) | AU2007269733B2 (https=) |
| BR (1) | BRPI0713935A2 (https=) |
| CA (1) | CA2656395C (https=) |
| CL (1) | CL2007001923A1 (https=) |
| CO (1) | CO6150126A2 (https=) |
| ES (2) | ES2616405T3 (https=) |
| MX (1) | MX2009000131A (https=) |
| NO (1) | NO20090467L (https=) |
| PE (1) | PE20080376A1 (https=) |
| TW (1) | TWI367112B (https=) |
| WO (1) | WO2008005353A2 (https=) |
| ZA (1) | ZA200900350B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| EP2120879A2 (en) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| US8624050B2 (en) * | 2007-06-22 | 2014-01-07 | General Electric Company | Solution process for transparent conductive oxide coatings |
| WO2009078999A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
| EP2438060B1 (en) | 2009-06-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Active metabolite of a thrombin receptor antagonist |
| JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
| CN102442965B (zh) * | 2010-09-30 | 2013-12-11 | 天津药物研究院 | 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途 |
| WO2017134200A1 (en) | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
| TR201601548A2 (tr) | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
| MX2020008137A (es) * | 2018-02-02 | 2020-10-19 | Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro | Formulaciones orales y usos de las mismas. |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61137813A (ja) * | 1984-12-07 | 1986-06-25 | Sawai Seiyaku Kk | 持続性セフラジン製剤 |
| JPS63162620A (ja) * | 1986-12-25 | 1988-07-06 | Teisan Seiyaku Kk | 遅溶性顆粒及びそれを用いた持続性複合顆粒 |
| GB9414045D0 (en) * | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| US20010003588A1 (en) * | 1996-09-12 | 2001-06-14 | Smithkline Beecham Corporation | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
| JPH10130142A (ja) * | 1996-10-31 | 1998-05-19 | Zensei Yakuhin Kogyo Kk | 放出持続型圧縮製剤 |
| JPH10298062A (ja) * | 1997-04-24 | 1998-11-10 | Pfizer Pharmaceut Co Ltd | 口腔内速溶型錠剤 |
| CZ298578B6 (cs) * | 1997-11-25 | 2007-11-14 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO2001000656A2 (en) | 1999-06-29 | 2001-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| US6630451B1 (en) | 1999-06-29 | 2003-10-07 | Orthomcneil Pharmaceutical, Inc. | Benzimidazolone peptidometics as thrombin receptor antagonist |
| US6858577B1 (en) | 1999-06-29 | 2005-02-22 | Ortho-Mcneil Pharmaceutical, Inc. | Indole peptidomimetics as thrombin receptor antagonists |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| AU6690001A (en) * | 2000-06-15 | 2001-12-24 | Schering Corp | Thrombin receptor antagonists |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| WO2002068425A1 (en) * | 2001-02-23 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| EP1394152A4 (en) | 2001-04-19 | 2005-02-02 | Eisai Co Ltd | 2-IMINOIMIDAZOLE DERIVATIVES (1) |
| KR100960170B1 (ko) * | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
| BRPI0309309B8 (pt) * | 2002-04-16 | 2021-05-25 | Merck Sharp & Dohme | antagonistas de receptor de trombina tricíclicos |
| DE10317816A1 (de) * | 2003-04-16 | 2004-11-04 | Claas Selbstfahrende Erntemaschinen Gmbh | Feldhäcksler mit positionierbarer Fahrerkabine |
| CZ300438B6 (cs) * | 2003-11-25 | 2009-05-20 | Pliva Hrvatska D.O.O. | Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| US20080026050A1 (en) * | 2006-06-30 | 2008-01-31 | Rajan Gupta | Solid dose formulations of a thrombin receptor antagonist |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| EP2120879A2 (en) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| BRPI0809095A2 (pt) * | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
-
2007
- 2007-06-28 TW TW096123547A patent/TWI367112B/zh not_active IP Right Cessation
- 2007-06-29 MX MX2009000131A patent/MX2009000131A/es unknown
- 2007-06-29 AR ARP070102934A patent/AR061790A1/es not_active Application Discontinuation
- 2007-06-29 CL CL200701923A patent/CL2007001923A1/es unknown
- 2007-06-29 ES ES07796595.2T patent/ES2616405T3/es active Active
- 2007-06-29 CA CA2656395A patent/CA2656395C/en active Active
- 2007-06-29 WO PCT/US2007/015168 patent/WO2008005353A2/en not_active Ceased
- 2007-06-29 ES ES12159636.5T patent/ES2616354T3/es active Active
- 2007-06-29 US US11/771,520 patent/US20080031943A1/en not_active Abandoned
- 2007-06-29 KR KR1020097000084A patent/KR20090023670A/ko not_active Withdrawn
- 2007-06-29 JP JP2009518301A patent/JP5116764B2/ja not_active Expired - Fee Related
- 2007-06-29 CN CN201510409546.7A patent/CN104922054A/zh active Pending
- 2007-06-29 EP EP12159636.5A patent/EP2491922B1/en active Active
- 2007-06-29 AU AU2007269733A patent/AU2007269733B2/en not_active Ceased
- 2007-06-29 CN CNA2007800325694A patent/CN101511345A/zh active Pending
- 2007-06-29 EP EP07796595.2A patent/EP2034969B1/en active Active
- 2007-06-29 BR BRPI0713935-7A patent/BRPI0713935A2/pt not_active IP Right Cessation
- 2007-07-02 PE PE2007000840A patent/PE20080376A1/es not_active Application Discontinuation
-
2009
- 2009-01-15 ZA ZA200900350A patent/ZA200900350B/xx unknown
- 2009-01-29 NO NO20090467A patent/NO20090467L/no not_active Application Discontinuation
- 2009-01-30 CO CO09008875A patent/CO6150126A2/es unknown
-
2012
- 2012-03-30 JP JP2012082021A patent/JP2012126752A/ja not_active Withdrawn
-
2016
- 2016-03-10 US US15/066,726 patent/US20170224666A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0713935A2 (pt) | 2012-12-04 |
| EP2491922A1 (en) | 2012-08-29 |
| ZA200900350B (en) | 2010-01-27 |
| US20170224666A9 (en) | 2017-08-10 |
| WO2008005353A2 (en) | 2008-01-10 |
| CO6150126A2 (es) | 2010-04-20 |
| CA2656395A1 (en) | 2008-01-10 |
| WO2008005353A3 (en) | 2008-06-26 |
| EP2034969A2 (en) | 2009-03-18 |
| JP2009542678A (ja) | 2009-12-03 |
| CL2007001923A1 (es) | 2008-02-08 |
| EP2491922B1 (en) | 2017-01-04 |
| AU2007269733B2 (en) | 2013-02-21 |
| US20160193196A1 (en) | 2016-07-07 |
| JP2012126752A (ja) | 2012-07-05 |
| US20080031943A1 (en) | 2008-02-07 |
| MX2009000131A (es) | 2009-01-26 |
| CN101511345A (zh) | 2009-08-19 |
| AR061790A1 (es) | 2008-09-24 |
| JP5116764B2 (ja) | 2013-01-09 |
| TW200810792A (en) | 2008-03-01 |
| NO20090467L (no) | 2009-03-19 |
| KR20090023670A (ko) | 2009-03-05 |
| CN104922054A (zh) | 2015-09-23 |
| CA2656395C (en) | 2016-12-13 |
| ES2616354T3 (es) | 2017-06-12 |
| ES2616405T3 (es) | 2017-06-13 |
| EP2034969B1 (en) | 2017-01-11 |
| AU2007269733A1 (en) | 2008-01-10 |
| TWI367112B (en) | 2012-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080376A1 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina | |
| AR118805A2 (es) | Terapia de combinación para el tratamiento de la diabetes | |
| CO6150163A2 (es) | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina | |
| UY32547A (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| ECSP077987A (es) | Formulación de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberación modificada | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| MA30781B1 (fr) | Inhibiteur de kinase | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| MX2023001812A (es) | Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
| CA2725933A1 (en) | Drug combinations comprising a dgat inhibitor and a ppar-agonist | |
| RU2008135718A (ru) | Композиции клопидогреля бисульфата | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| PE20121131A1 (es) | Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina | |
| CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| PE20070698A1 (es) | Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol | |
| JOP20170197A1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| ECSP055762A (es) | 4-amino-1-(piridilmetil)piperidina sustituida como antagonistas de receptores muscarinicos | |
| ES2556235T3 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3 | |
| PE20060768A1 (es) | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |